Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeCLINICAL TRIALS, STUDIES, DATAPRELUDE-BTK Study Results Presented at LINC Confirms Serranator Device Novel Mechanism of...

PRELUDE-BTK Study Results Presented at LINC Confirms Serranator Device Novel Mechanism of Action

Fe bruary 1, 2021

PRELUDE-BTK Study was presented at this year’s LINC Symposium on January 29th. PRELUDE-BTK Study, was a prospective, single-arm, multi-center feasibility study to show the safety and efficacy of Serration Angioplasty.

The study was led by co-Principal Investigators, Drs. Andrew Holden (Auckland, New Zealand), who presented the data, and Michael Lichtenberg (Arnsberg, Germany). Four other centers from Europe participated in the trial which included 30-day and 6-month follow up.

The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon FDA Cleared and CE Marked that embeds serration technology into a semi-compliant balloon for treating Peripheral Artery Disease (PAD). The device is designed to create multiple longitudinal lines of interrupted micro-serrations to aid arterial expansion.

Forty-six subjects were treated with the Serranator device and 53 lesions were analyzed by the core lab. The average final residual stenosis was 21.8%, with an average BTK arterial lumen gain of 1.55mm. These results were achieved with a low average maximum atmospheric pressure of 6 atmospheres. The bailout stent rate was 1.9%. A subset of lesions (n=10) were imaged with OCT and IVUS and analyzed by a core lab. All showed a serration effect. At 30 days the freedom from primary safety events was 95.7%. The freedom from clinically driven-TLR was 97.7% with 70% of subjects achieving 1 or more RCC improvement at 6 months. There were no Serious Adverse Events related to the device.

“Today, we have insufficient data for effective lesion revascularization in BTK arteries. Based on published POBA data, especially in calcified lesions, more than 40% of the cases result in complex dissections and significant recoil phenomenon. This ultimately leads to scaffold implantation to stabilize the lumen and prevent diminished outflow. This revascularization strategy is associated with poor patency outcomes,” stated the study’s Co-PI, Dr. Michael Lichtenberg.

“The PRELUDE study clearly proved the hypothesis, that hemodynamic and morphologic success in BTK revascularization is strongly associated with vessel compliance improvement. We need to concentrate first on this aspect, before we can discuss the need for longer-term restenosis prevention with antiproliferative substances. We know that dissections are directly associated with loss of patency and impaired wound healing. Prevention of dissections within a rigid, non-compliant vessel, along with luminal gain can only be successful with a vessel wall modification device that applies low atmospheres. The PRELUDE-BTK study clearly showed that the mechanism of action works well enough that it does not even need additional antiproliferative treatment, as CD-TLR was only 2.3% after 6 months,” continued Dr. Lichtenberg.

Carol A. Burns, President and CEO of Cagent Vascular added, “These study data confirm that the Serranator device has a unique mechanism of action that led to these positive results. The concept of adding serrated strips to a balloon is vastly different from a plain balloon. Serration technology with point force capability is the innovation that we have desperately needed for decades old angioplasty. This may change how all angioplasty is performed in the future. The product was recently launched in the US and the EU. The clinical feedback and acute outcomes from users outside the trial appear to replicate these study data. As we expand our commercial efforts, we look forward to making this technology accessible to more physicians to help treat patients afflicted with CLTI.”

Dr. Venita Chandra, Vascular Surgeon from Stanford University added, “I have been very impressed with the luminal gain that can be achieved at low atmospheric pressures provided by serration angioplasty, even in heavily calcified vessels. In addition, the luminal gain in the setting of minimal dissection, and less vessel recoil than POBA, makes this a very compelling new tool for BTK disease. I also think this is a very promising tool for pedal arch angioplasty.”

The Serranator product offering for the infrapopliteal indication is available in 2.5, 3.0, 3.5mm balloon diameters and 40, 80 and 120mm balloon lengths. The Company has initiated US and EU sales and plans to expand its commercial efforts later this year.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy